JOHN B. HENNEMAN III - 05 Jun 2025 Form 4 Insider Report for Aprea Therapeutics, Inc. (APRE)

Role
Director
Signature
/s/ John Hamill, as Attorney-in-Fact
Issuer symbol
APRE
Transactions as of
05 Jun 2025
Net transactions value
$0
Form type
4
Filing time
09 Jun 2025, 16:05:29 UTC
Previous filing
19 Nov 2024
Next filing
23 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
HENNEMAN JOHN B III Director 3805 OLD EASTON ROAD, DOYLESTOWN /s/ John Hamill, as Attorney-in-Fact 09 Jun 2025 0001187572

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APRE Common Stock Award $0 +1,045 +11% $0.000000 10,229 05 Jun 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APRE Stock Options (Right to Buy) Award $0 +4,185 $0.000000 4,185 05 Jun 2025 Common Stock 4,185 $1.81 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares represent restricted stock units which were granted on June 5, 2025, and which will vest and be settled in common stock on June 5, 2026, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.
F2 The option vests in full on June 5, 2026, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.